A Phase 2 Trial Assessing Osimertinib Activity Against Leptomeningeal Carcinomatosis in EGFR-Mutant Lung Cancer

被引：1

作者：

Akazawa, Y. ^{[1
]}

Nanjo, S. ^{[2
]}

Tamiya, M. ^{[3
]}

Hata, A. ^{[4
]}

Yamaguchi, T. ^{[5
]}

Kumagai, T. ^{[3
]}

Mori, M. ^{[1
]}

Katakami, N. ^{[6
]}

机构：

[1] Natl Hosp Org Toneyama Natl Hosp, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[2] Univ Calif San Francisco, Div Oncol, San Francisco, CA 94143 USA

[3] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan

[4] Kobe Minimally Invas Canc Ctr, Dept Pulm Oncol, Kobe, Hyogo, Japan

[5] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, Toyonaka, Osaka, Japan

[6] Takarazuka City Hosp, Med Oncol, Takarazuka, Hyogo, Japan

来源：

关键词：

Osimertinib; leptomeningeal carcinomatosis; Acquired resistance;

D O I：

10.1016/j.jtho.2019.08.1992

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP1.01-13

引用

页码：S918 / S918

页数：1